BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 24942023)

  • 1. The biology of relapsed acute lymphoblastic leukemia: opportunities for therapeutic interventions.
    Bhatla T; Jones CL; Meyer JA; Vitanza NA; Raetz EA; Carroll WL
    J Pediatr Hematol Oncol; 2014 Aug; 36(6):413-8. PubMed ID: 24942023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The genomic landscape of pediatric acute lymphoblastic leukemia and precision medicine opportunities.
    Tran TH; Hunger SP
    Semin Cancer Biol; 2022 Sep; 84():144-152. PubMed ID: 33197607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genomic characterization of paediatric acute lymphoblastic leukaemia: an opportunity for precision medicine therapeutics.
    Tasian SK; Hunger SP
    Br J Haematol; 2017 Mar; 176(6):867-882. PubMed ID: 27984637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia.
    Schotte D; De Menezes RX; Akbari Moqadam F; Khankahdani LM; Lange-Turenhout E; Chen C; Pieters R; Den Boer ML
    Haematologica; 2011 May; 96(5):703-11. PubMed ID: 21242186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment and biology of pediatric acute lymphoblastic leukemia.
    Kato M; Manabe A
    Pediatr Int; 2018 Jan; 60(1):4-12. PubMed ID: 29143423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple drug resistance protein (MDR-1), multidrug resistance-related protein (MRP) and lung resistance protein (LRP) gene expression in childhood acute lymphoblastic leukemia.
    Valera ET; Scrideli CA; Queiroz RG; Mori BM; Tone LG
    Sao Paulo Med J; 2004 Jul; 122(4):166-71. PubMed ID: 15543372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Building better therapy for children with acute lymphoblastic leukemia.
    Carroll WL; Raetz EA
    Cancer Cell; 2005 Apr; 7(4):289-91. PubMed ID: 15837616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Profiling gene mutations, translocations, and multidrug resistance in pediatric acute lymphoblastic leukemia: a step forward to personalizing medicine.
    Rose-James A; Shiji R; Kusumakumary P; Nair M; George SK; Sreelekha TT
    Med Oncol; 2016 Sep; 33(9):98. PubMed ID: 27449773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults.
    Ronson A; Tvito A; Rowe JM
    Curr Oncol Rep; 2016 Jun; 18(6):39. PubMed ID: 27207612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cytogenetics and in vitro drug resistance of acute leukemia in children and adults].
    Styczyński J; Haus O
    Postepy Hig Med Dosw (Online); 2006; 60():527-37. PubMed ID: 17060894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Childhood acute lymphoblastic leukemia: Integrating genomics into therapy.
    Tasian SK; Loh ML; Hunger SP
    Cancer; 2015 Oct; 121(20):3577-90. PubMed ID: 26194091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Towards personalized therapy in pediatric acute lymphoblastic leukemia: RAS mutations and prednisolone resistance.
    Ariës IM; van den Dungen RE; Koudijs MJ; Cuppen E; Voest E; Molenaar JJ; Caron HN; Pieters R; den Boer ML
    Haematologica; 2015 Apr; 100(4):e132-6. PubMed ID: 25480501
    [No Abstract]   [Full Text] [Related]  

  • 13. Genomic and pharmacogenetic studies of childhood acute lymphoblastic leukemia.
    Pui CH
    Front Med; 2015 Mar; 9(1):1-9. PubMed ID: 25511622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relapse of acute lymphoblastic leukemia in children in the context of microarray analyses.
    Szczepanek J; Styczyński J; Haus O; Tretyn A; Wysocki M
    Arch Immunol Ther Exp (Warsz); 2011 Feb; 59(1):61-8. PubMed ID: 21246408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New targeted therapies for relapsed pediatric acute lymphoblastic leukemia.
    Pierro J; Hogan LE; Bhatla T; Carroll WL
    Expert Rev Anticancer Ther; 2017 Aug; 17(8):725-736. PubMed ID: 28649891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance revealed in acute lymphoblastic leukemia.
    Aster JC; DeAngelo DJ
    Nat Med; 2013 Mar; 19(3):264-5. PubMed ID: 23467232
    [No Abstract]   [Full Text] [Related]  

  • 17. Childhood acute lymphoblastic leukemia: update on prognostic factors.
    Vrooman LM; Silverman LB
    Curr Opin Pediatr; 2009 Feb; 21(1):1-8. PubMed ID: 19242236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive value of multidrug resistance proteins and cellular drug resistance in childhood relapsed acute lymphoblastic leukemia.
    Styczynski J; Wysocki M; Debski R; Czyzewski K; Kolodziej B; Rafinska B; Kubicka M; Koltan S; Koltan A; Pogorzala M; Kurylak A; Olszewska-Slonina D; Balwierz W; Juraszewska E; Wieczorek M; Olejnik I; Krawczuk-Rybak M; Kuzmicz M; Kowalczyk J; Stefaniak J; Badowska W; Sonta-Jakimczyk D; Szczepanski T; Matysiak M; Malinowska I; Stanczak E; Wachowiak J; Konatkowska B; Gil L; Balcerska A; Maciejka-Kapuscinska L
    J Cancer Res Clin Oncol; 2007 Nov; 133(11):875-93. PubMed ID: 17671794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Network-based expression analysis reveals key genes related to glucocorticoid resistance in infant acute lymphoblastic leukemia.
    Mousavian Z; Nowzari-Dalini A; Stam RW; Rahmatallah Y; Masoudi-Nejad A
    Cell Oncol (Dordr); 2017 Feb; 40(1):33-45. PubMed ID: 27798768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia.
    Oshima K; Zhao J; Pérez-Durán P; Brown JA; Patiño-Galindo JA; Chu T; Quinn A; Gunning T; Belver L; Ambesi-Impiombato A; Tosello V; Wang Z; Sulis ML; Kato M; Koh K; Paganin M; Basso G; Balbin M; Nicolas C; Gastier-Foster JM; Devidas M; Loh ML; Paietta E; Tallman MS; Rowe JM; Litzow M; Minden MD; Meijerink J; Rabadan R; Ferrando A
    Nat Cancer; 2020 Nov; 1(11):1113-1127. PubMed ID: 33796864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.